Home Featured Page 201

Featured

Latest

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

Year in Review: Psychedelics in 2025 (Video)

The Psychedelic News Feed: December 15 – 21, 2025

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R)...

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

Psychedelic Research Bulletin: November 2021

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix...

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

1...200201202...305 Page 201 of 305

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

Year in Review: Psychedelics in 2025 (Video)

The Psychedelic News Feed: December 15 – 21, 2025

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R)...

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

Psychedelic Research Bulletin: November 2021

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix...

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug...

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

EDITOR PICKS

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Chronic Pain, Illicit Markets, and a Preventable Pipeline to Addiction

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY